Moreover, in phase 1b, 15 patients (38%) had previously received anti-EGFR mAb therapy (cetuximab or nituzumab), including 3 patients with CRC, 6 with SCCHN, and 6 with NPC. This evidence concerns the gene EGFR and nasopharyngeal carcinoma.